Algorae boosts AlgoraeRx sales leadership with hospital market veteran

Living Cell Technologies ( (AU:1AI) ) has issued an announcement.

Algorae Pharmaceuticals has appointed veteran pharmaceutical executive Waleed Elsayed as Head of Sales for its commercial arm AlgoraeRx, reinforcing its leadership bench as it pushes to scale in the Australian and New Zealand hospital markets. Elsayed, who brings more than two decades of experience across Sandoz and Baxter in hospital sales, national account management and specialty pharma, will start in the role in the second quarter of 2026.

The hire is designed to sharpen AlgoraeRx’s in‑market execution and build a high‑impact, customer‑centric sales organisation as the company broadens its portfolio of generic and specialty medicines. Management is positioning the move as critical to driving sustainable revenue growth and strengthening strategic partnerships, signalling a more aggressive commercial phase to complement Algorae’s AI‑driven drug discovery activities.

The most recent analyst rating on (AU:1AI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.

More about Living Cell Technologies

Algorae Pharmaceuticals is an ASX-listed, AI-enabled pharmaceutical company focused on drug-combination discovery and pharmaceutical commercialisation. Its proprietary AlgoraeOS platform uses artificial intelligence to identify synergistic drug combinations and guide preclinical experiments, while its AlgoraeRx division sources, licenses and supplies generic and specialty medicines in Australia and New Zealand through manufacturing partners and established distribution channels.

YTD Price Performance: 7.14%

Average Trading Volume: 1,473,502

Technical Sentiment Signal: Hold

Current Market Cap: A$25.75M

For a thorough assessment of 1AI stock, go to TipRanks’ Stock Analysis page.